| Literature DB >> 26213526 |
J Nazaruk1, M Borzym-Kluczyk2.
Abstract
Diabetes mellitus is a chronic metabolic disease which is a serious global problem. In 2010 an estimated 285 million people had diabetes and within the next 20 years this value is expected to almost double. Many antidiabetic therapies focus on improving insulin sensitivity, increasing insulin production, and/or decreasing the level of blood glucose. Although a number of synthetic medicines are available, drugs of natural origin have aroused great interest. Triterpenes seem to demonstrate adequate properties. Many experiments have shown that these compounds have several antidiabetic mechanisms. They can inhibit enzymes involved in glucose metabolism, prevent the development of insulin resistance and normalize plasma glucose and insulin levels. These natural compounds, in contrast to synthetic drugs, apart from producing a hypoglycemic effect have also been found to manifest hypolipidemic and anti-obesity activity. Triterpenes are also promising agents in the prevention of diabetic complications. They have strong antioxidant activity and inhibit the formation of advanced glycation end products, implicated in the pathogenesis of diabetic nephropathy, embryopathy, neuropathy or impaired wound healing. Until now very few clinical studies have been concerned with the application of triterpenes in treating diabetes. However, due to their great therapeutic potential, these compounds deserve special attention.Entities:
Keywords: Diabetes mellitus; Natural products; Triterpenes
Year: 2014 PMID: 26213526 PMCID: PMC4513225 DOI: 10.1007/s11101-014-9369-x
Source DB: PubMed Journal: Phytochem Rev ISSN: 1568-7767 Impact factor: 5.374
Fig. 1Chemical structures of the main subclasses of triterpenes
Fig. 2Inhibitory effect of triterpenes on sorbitol pathway
Triterpenoid inhibitors of PTP 1B
| Compound | IC50 (μM) | Plant (family) | References |
|---|---|---|---|
| 3-Oxoolean-12-en-27-oic acid | 6.8 |
| Na et al. ( |
| 3 | 5.2 | ||
| 3 | 4.9 | ||
| 3 | 11.7 | ||
| 3 | 12.8 | ||
| Oleanolic acid | 3.9 | – | |
| 9.5 |
| Ramírez-Espinosa et al. ( | |
| 14.4 |
| Sasaki et al. ( | |
| 3 | 5.2 |
| Kwon et al. ( |
| 3 | 7.8 | ||
| 3 | 9.3 | ||
| Ursolic acid | 2.3 |
| Ramírez-Espinosa et al. ( |
| 3.08 |
| Zhang et al. ( | |
| 3.8 |
| Na et al. ( | |
| 4.1 |
| Sasaki et al. ( | |
| 3.1 |
| Choi et al. ( | |
| Moronic acid | 13.2 |
| Ramírez-Espinosa et al. ( |
| Morolic acid | 9.1 | ||
| Corosolic acid | 7.2 |
| Na et al. ( |
| 7.0 |
| Choi et al. ( | |
| 2 | 29.1 |
| Na et al. ( |
| 2 | 5.3 | ||
| Rhododendric acid | 6.3 |
| Choi et al. ( |
| (20 | 15.2 |
| Zhang et al. ( |
| (20 | 8.4 | ||
| 3 | 13.1 | ||
| Lupeol | 5.6 |
| Na et al. ( |
| Lupenone | 13.7 | ||
| Hopane-6α,22-diol | 3.7 |
| Seo et al. ( |
| Brialmontin 1 | 14.0 |
Fig. 3Triterpenes as PTP 1B inhibitors
Fig. 4The influence of gymnemic acid on glycerol metabolism
Fig. 5The action of triterpenes on glycogen phosphorylase
Fig. 6The role of triterpenes in cortisone metabolism
In vitro studies on antidiabetic activity of triterpenes
| Plant (family) | Compound | Model | Result | References |
|---|---|---|---|---|
|
| Karaviloside XI Momordicoside S 19-Epoxycucurbita-6-ene-23( 3-O- 25-tetrahydroxycucurbit-5-ene Momordicine II Kuguaglycoside G | L6 muscle cells, 3T3L1 adipocytes MIN6 | ↑GLUT4 translocation ↑ AMPK ↑ Insulin secretion | Tan et al. ( Keller et al. ( |
|
| Pachymic acid | 3T3-L1 adipocytes | ↑ GLUT4 ↑ Phosphorylation of insulin receptor substrate (IRS)-1 ↑ Akt and AMPK | Huang et al. ( |
|
| Ginsenoside Rc | C2C12 myotubes | ↑ Glucose uptake via activation of p38MAPK and AMPK thanks intracellular ROS generation | Lee et al. ( |
|
| Ursolic acid | CHO/IR cells 3T3-L1 adipocytes | ↑ IR ↑ Phosphorylation of the IR ↑ Insulin-stimulated GLUT4 translocation | Jung et al. ( |
|
| 7 7 | Huh7 cells (human hepatic cells) | ↑ Phosphorylation of IR (in the absence of insulin ↑ Insulin-mediated IR tyrosine phosphorylation (only 1) | Ardiles et al. ( |
| – | Astragaloside IV | 3T3-L1 adipocytes | ↑ Insulin stimulated 2-DOG uptake, antagonized the TNF | Jiang et al. ( |
Antidiabetic activity of triterpenes tested in animal models
| Plant (family) | Compound | Model | Result | References |
|---|---|---|---|---|
|
| Momordicoside S momordicoside T | Insulin-sensitive and insulin-resistant mice | ↑ Glucose tolerance ↑ Fatty acid oxidation | Tan et al. ( |
|
| Extract containing above 50 % of triterpene acids (tormentic, corosolic, maslinic, oleanolic and ursolic acid) | Alloxan- and STZ-diabetic mice, HFD mice | ↑ Serum insulin level ↑ SOD ↓ Glycosylated serum protein ↓ Total cholesterol and triglyceride reversing of insulin resistance | Lü et al. ( |
|
| Lanostane-type terpenoids: dehydrotumulosic acid, dehydrotrametenolic acid, pachymic acid | Diadetic db/db STZ-treated mice | ↓ Postprandial blood glucose level ↑ Insulin sensitivity | Sato et al. ( |
|
|
| STZ-diabetic mice with HFD-induced hyperlipidemia | ↓ Blood glucose, ↓ Total cholesterol and serum triglycerides | Santos et al. ( |
| – | Oleanolic acid | STZ-diabetic mice | ↓ Glucose and triacylglycerides level ↓ Body weight ↓ Oxidative stress ↓ Gluconeogenesis in the liver mediated by the Akt/FoxO1 axis ↑ Insulin signal transduction in hepatocytes ↑ Glucose tolerance | Wang et al. ( |
| – | Maslinic acid | KK-Ay mice (genetic type 2-diabetes) | ↓ Blood glucose level ↓ Glycogenolysis via the inhibition of glycogen phosphorylase | Liu et al. ( |
| – | Asiatic acid | STZ-diabetic mice | ↓ Blood glucose level ↓ Serum insulin level ↑ ↑ | Liu et al. ( |
| – | Ursolic acid | STZ-diabetic mice | ↓ Blood glucose level ↑ Plasma and pancreatic insulin concentrations preservation of pancreatic | Jang et al. ( |
| – | Astragaloside IV | HFD-STZ-diabetic mice | ↓ Blood glucose level ↓ Blood insulin level ↓Hepatic GP and G6Pase activities | Lv et al. ( |
Fig. 7The scheme of consequences of hyperglycemia in kidney tissue and serum